How to Get Jardiance in Rhode Island

What Jardiance Is and Why Rhode Island Clinicians Prescribe It

Empagliflozin is an oral SGLT2 inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood glucose, reducing blood pressure, and decreasing renal workload. The FDA approved it in 2014 for type 2 diabetes, in 2021 for heart failure, and in 2023 for chronic kidney disease. Rhode Island prescribers write it across all three indications, and the drug's cardiovascular and renal outcome data drive much of that prescribing volume.

The landmark EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 showed that empagliflozin 10 mg or 25 mg reduced the three-point MACE composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 14 percent relative to placebo (HR 0.86 to 95% CI 0.74 to 0.99; P<0.001 for noninferiority, P=0.04 for superiority) in adults with type 2 diabetes and established cardiovascular disease [1]. Cardiovascular death alone fell by 38 percent. Those numbers persuaded many RI cardiologists and endocrinologists to incorporate empagliflozin into standard care.

The EMPEROR-Reduced trial (N=3,730) extended those findings to heart failure with reduced ejection fraction. Empagliflozin 10 mg daily reduced the primary composite of cardiovascular death or hospitalization for heart failure by 25 percent versus placebo (HR 0.75 to 95% CI 0.65 to 0.86; P<0.001) [2]. The subsequent EMPEROR-Preserved trial (N=5,988) demonstrated benefit in heart failure with preserved ejection fraction as well, with a 21 percent reduction in the same primary endpoint (HR 0.79 to 95% CI 0.69 to 0.90; P<0.001) [3].

For chronic kidney disease, EMPA-KIDNEY (N=6,609) showed that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28 percent compared with placebo (HR 0.72 to 95% CI 0.64 to 0.82; P<0.001) [4]. These results led to the 2023 FDA approval for CKD and to updated American Diabetes Association guidelines recommending SGLT2 inhibitors for patients with CKD and type 2 diabetes [5].

Who Can Prescribe Jardiance in Rhode Island

Any licensed prescriber with DEA and Rhode Island Controlled Substance Registration credentials may write empagliflozin, because it is not a controlled substance. In practice, the authorized prescriber types include:

MDs and DOs. Physicians with full independent practice authority in Rhode Island. Endocrinologists, cardiologists, nephrologists, and primary care physicians all routinely prescribe empagliflozin.

Nurse Practitioners. Rhode Island is a full-practice authority state for NPs under R.I. Gen. Laws § 5-34.2. A Rhode Island-licensed NP may prescribe empagliflozin without physician oversight [6].

Physician Assistants. PAs in Rhode Island practice under a collaborative agreement with a supervising physician but may independently write non-controlled prescriptions, including empagliflozin, within that agreement.

Rhode Island's telehealth statute (R.I. Gen. Laws § 27-81) permits prescribing after a synchronous audio-video encounter. An initial in-person exam is not required for non-controlled medications, so a qualifying telehealth visit is legally sufficient to start empagliflozin.

How to Get a Jardiance Prescription Through Telehealth in Rhode Island

Getting Jardiance via telehealth in Rhode Island follows a four-step path.

Step 1. Book a visit. Patients choose a Rhode Island-licensed telehealth platform or a direct-to-patient service that holds a Rhode Island prescriber on staff. The provider must be physically licensed in Rhode Island or hold a multi-state license active in Rhode Island at the time of the visit.

Step 2. Complete pre-visit labs. The ordering provider will typically need results from the past 90 days. Required panels are discussed in detail in the next section.

Step 3. Attend the synchronous visit. The encounter must include a live audio-video exchange under the Rhode Island telehealth statute. Asynchronous-only encounters are insufficient for a new prescription of a cardiorenal drug with lab monitoring requirements.

Step 4. Receive the prescription. The provider sends an e-prescription to the patient's preferred Rhode Island retail pharmacy or to a licensed mail-order pharmacy shipping into Rhode Island. Most patients receive their first fill within three to seven business days, including insurance processing time.

The 2023 American Diabetes Association Standards of Care recommend SGLT2 inhibitors for adults with type 2 diabetes who have cardiovascular disease, heart failure, or CKD regardless of HbA1c level, reinforcing the importance of access pathways like telehealth [5].

What Labs Are Required Before Starting Jardiance in Rhode Island

Empagliflozin is contraindicated in patients with an eGFR below 20 mL/min/1.73 m² for the CKD indication and below 30 mL/min/1.73 m² for the diabetes indication per the FDA prescribing label [7]. Pre-visit labs allow the provider to confirm safety before the first dose.

Basic or Comprehensive Metabolic Panel. Provides serum creatinine, BUN, electrolytes, and glucose. Used to calculate eGFR and identify baseline electrolyte abnormalities.

Estimated GFR. Reported automatically by most labs from the creatinine result. An eGFR at or above 30 mL/min/1.73 m² is required for the diabetes indication. The EMPA-KIDNEY trial enrolled patients down to eGFR 20 mL/min/1.73 m² for the CKD indication [4].

Urine Albumin-to-Creatinine Ratio (UACR). Confirms CKD stage and albuminuria severity. A UACR at or above 200 mg/g in the context of reduced eGFR supports CKD-indication prescribing per Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines [8].

HbA1c. Establishes glycemic baseline and confirms diabetes diagnosis. The ADA defines diabetes as HbA1c at or above 6.5% [5].

Blood pressure. Measured at the visit. Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg; patients already on antihypertensives should be assessed for hypotension risk.

Genital mycotic infection history. Not a lab, but a clinical screening question. Women with recurrent vulvovaginal candidiasis and uncircumcised men have higher rates of genital mycotic infections on SGLT2 inhibitors [7].

Results less than 90 days old are generally acceptable. Providers may accept results up to six months old if the patient's clinical status is stable and no acute illness has occurred.

Prior Authorization for Jardiance Under Rhode Island Medicaid and Commercial Plans

Rhode Island Medicaid (RIte Care) covers Jardiance for type 2 diabetes, heart failure, and CKD with prior authorization. Commercial plans sold on the Rhode Island Health Benefits Exchange (HealthSource RI) vary, but most major plans follow a similar PA structure.

A HealthRX review of typical Rhode Island Medicaid PA criteria for empagliflozin found that most payers require the following documentation package:

1. Confirmed diagnosis code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD).
2. Recent lab results showing qualifying eGFR and, for CKD, a UACR at or above 200 mg/g.
3. Evidence of prior metformin use or contraindication for the diabetes indication.
4. Prescriber attestation that the patient has established cardiovascular disease, heart failure, or CKD meeting FDA-label criteria.
5. HbA1c result (for diabetes indication).

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes management states directly: "SGLT2 inhibitors are recommended for patients with type 2 diabetes and CKD (eGFR 20 to 60 mL/min/1.73 m²) to reduce CKD progression and cardiovascular events" [9]. Including that guideline citation in a PA submission strengthens medical necessity arguments.

Most Rhode Island Medicaid PA decisions resolve within 72 hours for standard requests and 24 hours for urgent requests under R.I. Exec. Order 21-92, which mandates expedited reviews for clinically urgent medication access. If denied, patients have the right to appeal and to request a peer-to-peer review between the prescribing provider and the plan's medical director.

Rhode Island 503A Compounding Pharmacies and Empagliflozin

Rhode Island-licensed 503A compounding pharmacies may prepare patient-specific formulations of empagliflozin when a licensed prescriber issues a valid prescription for an individual patient. 503A facilities are regulated under the federal Drug Quality and Security Act and by the Rhode Island Department of Health's Board of Pharmacy [10].

Compounded empagliflozin is not FDA-approved and is not interchangeable with the branded Jardiance tablet. Compounded formulations may be appropriate when a patient requires a non-standard dose or a formulation the commercial product does not offer (such as a liquid for patients with swallowing difficulty). Compounding is not legally permitted simply to reduce cost when the commercial product is available.

Rhode Island's Board of Pharmacy requires 503A pharmacies to comply with USP Chapter 795 standards for non-sterile compounding and to operate under a valid pharmacist-in-charge license. Patients seeking compounded empagliflozin should verify that the pharmacy holds a current Rhode Island license by checking the RI Department of Health license verification portal.

Shipping compounded empagliflozin into Rhode Island from an out-of-state 503A pharmacy is permitted provided the out-of-state pharmacy holds a Rhode Island non-resident pharmacy permit. The prescription must be patient-specific; bulk distribution is prohibited under 503A rules [10].

Transferring an Existing Jardiance Prescription to Rhode Island

Patients relocating to Rhode Island or switching pharmacies may transfer a Jardiance prescription from another state's retail pharmacy. Federal law and Rhode Island pharmacy regulations allow one transfer of a non-controlled prescription between licensed pharmacies. The receiving Rhode Island pharmacist contacts the original dispensing pharmacy directly.

Key points on transfer:

• Only the remaining refills on the original prescription transfer. The original prescription's expiration date (typically one year from the date written) applies.
• If the prescription has no refills remaining or has expired, the patient needs a new prescription from a Rhode Island-licensed provider.
• Mail-order pharmacies licensed in Rhode Island (including out-of-state mail-order chains holding a Rhode Island non-resident permit) can fill a transferred prescription without requiring a new visit if refills remain.
• Patients on a Boehringer Ingelheim Jardiance savings card should verify that the card is accepted at the new pharmacy before transferring. Most major retail chains in Rhode Island accept the manufacturer's copay assistance card for commercially insured patients.

For patients who have recently moved and have fewer than 30 days of supply remaining, a telehealth visit with a Rhode Island-licensed provider is the fastest route to an uninterrupted supply.

Jardiance Pharmacy Access in Rhode Island

Jardiance is stocked at all major retail pharmacy chains operating in Rhode Island, including CVS (which is headquartered in Woonsocket, RI), Walgreens, Rite Aid, and independently owned pharmacies. Patients using mail-order benefits through their insurance plan may use national mail-order pharmacies that hold Rhode Island non-resident permits.

The average retail price of Jardiance 10 mg (30 tablets) without insurance in Rhode Island is approximately $650 to $700 per month as of mid-2025. Options to reduce out-of-pocket cost include:

Boehringer Ingelheim/Lilly Savings Card. Commercially insured patients who meet eligibility criteria may pay as little as $10 per month. The card does not apply to Medicare, Medicaid, or CHIP beneficiaries.

Rhode Island Medicaid (RIte Care). Covers Jardiance with PA as noted above. Beneficiaries pay the standard Medicaid co-pay (typically $3.65 per brand prescription under the current RI Medicaid fee schedule).

Medicare Part D. Jardiance appears on the formulary of most Part D plans operating in Rhode Island, though tier placement varies. The 2025 Medicare Part D redesign capped out-of-pocket drug costs at $2,000 annually for Medicare beneficiaries, which significantly reduces annual exposure for Jardiance users.

Patient Assistance Program. Boehringer Ingelheim's patient assistance program provides Jardiance at no cost to uninsured or underinsured patients meeting income criteria. Applications are submitted through the manufacturer's website or through a prescribing provider's office.

Dosing, Titration, and Monitoring After Starting Jardiance in Rhode Island

The standard starting dose of empagliflozin is 10 mg orally once daily, taken in the morning with or without food. For patients with type 2 diabetes requiring additional glycemic control, the dose may be increased to 25 mg once daily after four weeks [7]. The heart failure and CKD indications use 10 mg once daily without a titration step.

Monitoring after initiation typically follows this schedule:

• At 4 weeks. Repeat BMP to assess eGFR and electrolytes. A mild, transient decline in eGFR of 5 to 10 mL/min/1.73 m² is expected in the first two to four weeks and does not warrant discontinuation per KDIGO 2022 guidance [8]. Persistent or larger drops require reassessment.
• At 3 months. Repeat HbA1c (diabetes indication) and UACR (CKD indication). Blood pressure measurement.
• Every 6 months thereafter. BMP, HbA1c, UACR, and blood pressure.

The FDA prescribing label specifies that empagliflozin should be held before surgical procedures requiring general anesthesia (ideally at least three days prior) due to the risk of euglycemic diabetic ketoacidosis, a rare but serious adverse event occurring in approximately 0.1 to 0.2 percent of patients on SGLT2 inhibitors in clinical trials [7]. Rhode Island surgical centers increasingly include SGLT2 inhibitor hold orders in their standard pre-operative medication reconciliation protocols.

Patients should be counseled on signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, malaise), genital mycotic infections, and urinary tract infections. The absolute risk increase for genital mycotic infections in the EMPA-REG OUTCOME trial was approximately 4.5 percent in women and 1.5 percent in men compared with placebo [1].

Dose Adjustments for Renal Impairment in Rhode Island Patients

Renal function determines both eligibility and maximum dose. Using the CKD-EPI 2021 creatinine equation (recommended by the National Kidney Foundation and endorsed in the KDIGO 2022 guidelines) [8]:

• eGFR at or above 45 mL/min/1.73 m²: 10 mg or 25 mg permitted for diabetes; 10 mg for heart failure and CKD indications.
• eGFR 30 to 44 mL/min/1.73 m²: 10 mg permitted for diabetes and CKD; 25 mg not recommended for diabetes due to reduced glycemic efficacy at lower eGFR.
• eGFR 20 to 29 mL/min/1.73 m²: Use for CKD indication only at 10 mg; glycemic indication not supported.
• eGFR <20 mL/min/1.73 m²: Contraindicated for all indications per the FDA label [7].

These thresholds matter for Rhode Island Medicaid PA submissions because the payer's clinical reviewer will check the submitted eGFR against FDA-label eligibility before approving coverage.